LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) announced today that the first three patients have been enrolled in the recently commenced Phase I clinical trial of its lead brain tumor vaccine product candidate. The vaccine trial is being conducted at the Johnny L. Cochran, Jr. Brain Tumor Center at Cedars-Sinai Medical Center in Los Angeles.
